Caris Life Sciences, ECOG-ACRIN and NRG Oncology Study Demonstrates Multimodal AI Approach to Predict Late Distant Recurrence Risk in HR+ Early Breast Cancer

Markets PR Newswire By PR Newswire 06 Aug 2026 12:30 1 min read
Caris Life Sciences, ECOG-ACRIN and NRG Oncology Study Demonstrates Multimodal AI Approach to Predict Late Distant Recurrence Risk in HR+ Early Breast Cancer

Findings published in Cancer Research Communications highlight potential to inform extended endocrine therapy decisions IRVING, Texas, Aug. 6, 2026 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading TechBio company, today announced the publication of a study in Cancer Research...

Covered in this story

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.